The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
|Slideshows|March 22, 2019
Dark Chocolate Fights Fatigue in Multiple Sclerosis
Author(s)Veronica Hackethal, MD
Because dark chocolate is relatively inexpensive-and many people like its taste-it could be a pragmatic adjunct to treatment in MS.
Advertisement
Advertisement
Related to this article
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Here's some of what is coming soon to NeurologyLive® this week.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP
3
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
4
Congress Passes ACT for ALS Reauthorization, Extending Research Programs
5